Subtopic Deep Dive

Topoisomerase Inhibition Resistance
Research Guide

What is Topoisomerase Inhibition Resistance?

Topoisomerase inhibition resistance refers to cellular mechanisms enabling cancer cells to evade death from topoisomerase-targeting drugs through mutations, efflux pumps, and enhanced DNA repair.

Cancer cells develop intrinsic or acquired resistance to topoisomerase inhibitors like topotecan via topoisomerase mutations and multidrug resistance proteins (Bukowski et al., 2020; Longley and Johnston, 2005). Structural studies reveal how camptothecin analogs poison topoisomerase I, with resistance linked to altered enzyme-DNA interactions (Staker et al., 2002). Over 1600 papers cite core resistance mechanisms, emphasizing efflux and repair pathways.

Curated Papers

Key Challenges

Why It Matters

Resistance to topoisomerase inhibitors limits chemotherapy efficacy in cancers like ovarian and colorectal, where topotecan failure rates exceed 50% due to acquired mutations (Longley and Johnston, 2005; Staker et al., 2002). Bukowski et al. (2020) detail efflux pumps like ABC transporters reducing intracellular drug levels, blocking treatment response. Overcoming resistance via combinations with DNA repair inhibitors improves survival, as modeled in cisplatin systems adaptable to topoisomerase contexts (Galluzzi et al., 2014). Nanocarrier strategies bypass efflux, enhancing delivery (Pérez-Herrero and Fernández-Medarde, 2015).

Key Research Challenges

Topoisomerase Mutations

Mutations in topoisomerase I and II alter drug binding sites, reducing poisoning efficiency (Staker et al., 2002). Crystal structures show topotecan intercalation disrupted by single amino acid changes. Identifying mutation-specific inhibitors remains unsolved (Bax et al., 2010).

Efflux Pump Overexpression

Multidrug resistance proteins expel topoisomerase inhibitors, lowering cytotoxicity (Bukowski et al., 2020). ABC transporters like MDR1 confer cross-resistance across chemotherapies (Longley and Johnston, 2005). Pump inhibitors show toxicity in trials.

DNA Repair Activation

Enhanced non-homologous end joining repairs topoisomerase-induced DNA breaks (Huang and Zhou, 2020). Resistance links to upregulated PARP and ATM pathways post-drug exposure. Combination therapies targeting repair sensitize cells (Galluzzi et al., 2014).

Essential Papers

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Edgar Pérez‐Herrero, Alberto Fernández‐Medarde · 2015 · European Journal of Pharmaceutics and Biopharmaceutics · 1.8K citations

Mechanisms of Multidrug Resistance in Cancer Chemotherapy

Karol Bukowski, Mateusz Kciuk, Renata Kontek · 2020 · International Journal of Molecular Sciences · 1.6K citations

Cancer is one of the main causes of death worldwide. Despite the significant development of methods of cancer healing during the past decades, chemotherapy still remains the main method for cancer ...

Molecular mechanisms of drug resistance

DB Longley, PG Johnston · 2005 · The Journal of Pathology · 1.6K citations

Abstract Resistance to chemotherapy limits the effectiveness of anti‐cancer drug treatment. Tumours may be intrinsically drug‐resistant or develop resistance to chemotherapy during treatment. Acqui...

Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance

Shiri Navon‐Venezia, Kira Kondratyeva, Alessandra Carattoli · 2017 · FEMS Microbiology Reviews · 1.2K citations

Klebsiella pneumoniae is an important multidrug-resistant (MDR) pathogen affecting humans and a major source for hospital infections associated with high morbidity and mortality due to limited trea...

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

Ruixue Huang, Ping‐Kun Zhou · 2020 · Signal Transduction and Targeted Therapy · 1.1K citations

Abstract Radiotherapy is one of the most common countermeasures for treating a wide range of tumors. However, the radioresistance of cancer cells is still a major limitation for radiotherapy applic...

Apoptosis induced by anticancer drugs

John A. Hickman · 1992 · Cancer and Metastasis Reviews · 871 citations

The mechanism of topoisomerase I poisoning by a camptothecin analog

Bart L. Staker, Kathryn A. Hjerrild, M.D. Feese et al. · 2002 · Proceedings of the National Academy of Sciences · 795 citations

We report the x-ray crystal structure of human topoisomerase I covalently joined to double-stranded DNA and bound to the clinically approved anticancer agent Topotecan. Topotecan mimics a DNA base ...

Reading Guide

Foundational Papers

Start with Longley and Johnston (2005) for broad resistance mechanisms including topoisomerase contexts; Staker et al. (2002) for topotecan-DNA-topoisomerase I structure essential to mutation resistance; Hickman (1992) links apoptosis evasion to drug failure.

Recent Advances

Bukowski et al. (2020) details efflux in chemotherapy resistance; Huang and Zhou (2020) covers DNA repair sensitization applicable to topoisomerase breaks; Pérez-Herrero and Fernández-Medarde (2015) on nanocarriers bypassing resistance.

Core Methods

X-ray crystallography for enzyme-inhibitor structures (Staker et al., 2002); gene knockdown for efflux validation (Bukowski et al., 2020); systems modeling of resistance networks (Galluzzi et al., 2014).

How PapersFlow Helps You Research Topoisomerase Inhibition Resistance

Discover & Search

Research Agent uses searchPapers('topoisomerase inhibition resistance cancer') to retrieve Bukowski et al. (2020, 1646 citations), then citationGraph reveals clusters around efflux mechanisms citing Longley and Johnston (2005). findSimilarPapers on Staker et al. (2002) uncovers structural resistance studies. exaSearch drills into mutation-specific papers from 250M+ OpenAlex corpus.

Analyze & Verify

Analysis Agent applies readPaperContent on Bukowski et al. (2020) to extract efflux gene lists, then runPythonAnalysis with pandas to quantify resistance fold-changes across datasets. verifyResponse via CoVe cross-checks mutation claims against Staker et al. (2002) structures. GRADE grading scores evidence strength for topotecan resistance pathways.

Synthesize & Write

Synthesis Agent detects gaps in efflux-topoisomerase combinations via contradiction flagging across Bukowski et al. (2020) and Galluzzi et al. (2014). Writing Agent uses latexEditText for resistance mechanism reviews, latexSyncCitations to link 10+ papers, and latexCompile for publication-ready drafts. exportMermaid generates pathway diagrams of mutation-efflux interactions.

Use Cases

"Analyze resistance fold-changes in topoisomerase inhibitor IC50 data from Bukowski et al."

Analysis Agent → readPaperContent (Bukowski 2020) → runPythonAnalysis (pandas plot IC50 histograms, NumPy stats) → matplotlib fold-change graph output.

"Draft LaTeX review on topoisomerase mutations and efflux in cancer resistance."

Synthesis Agent → gap detection (Staker 2002 + Longley 2005) → Writing Agent → latexEditText (structure sections) → latexSyncCitations (10 papers) → latexCompile → PDF review.

"Find GitHub repos modeling topoisomerase resistance simulations."

Research Agent → paperExtractUrls (Galluzzi 2014) → paperFindGithubRepo (cisplatin models) → githubRepoInspect → Python scripts for DNA repair dynamics.

Automated Workflows

Deep Research workflow scans 50+ papers on 'topoisomerase resistance mechanisms' via searchPapers → citationGraph → structured report with GRADE-scored sections on mutations (Staker et al., 2002). DeepScan's 7-step chain analyzes Bukowski et al. (2020) abstracts → CoVe verification → Python stats on resistance metrics. Theorizer generates hypotheses linking efflux to topotecan structures from Longley and Johnston (2005).

Try Doxa for Topoisomerase Inhibition Resistance Research

Frequently Asked Questions

What defines topoisomerase inhibition resistance?

Cancer cells resist via topoisomerase mutations reducing drug binding, efflux pumps expelling inhibitors, and DNA repair resolving strand breaks (Longley and Johnston, 2005; Staker et al., 2002).

What are main methods studying resistance?

Crystal structures reveal topotecan binding (Staker et al., 2002); gene expression profiles identify efflux upregulation (Bukowski et al., 2020); systems biology models cisplatin parallels (Galluzzi et al., 2014).

What are key papers?

Longley and Johnston (2005, 1627 citations) on general mechanisms; Bukowski et al. (2020, 1646 citations) on multidrug resistance; Staker et al. (2002, 795 citations) on topoisomerase I poisoning.

What open problems exist?

No universal biomarkers for mutation-efflux profiles; combination therapies lack clinical validation; predicting resistance evolution from structural data unsolved (Huang and Zhou, 2020).